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reating Sleep Apnea
n Heart Failure Patients
romises But Still No Prizes*
irend K. Somers, MD, PHD, FACC,
poor S. Gami, MD, Lyle J. Olson, MD, FACC
ochester, Minnesota
n North American and Western European middle-age
opulations, the prevalence of obstructive sleep apnea
OSA), as defined by the American Academy of Sleep
edicine, is as high as 20% (1). The majority of
ndividuals with OSA remain undiagnosed, and OSA and
eart failure (HF) often coexist (2,3). They share numer-
us risk factors and pathophysiologic mechanisms, which
ogether may contribute to HF progression or refracto-
iness to therapy. Moreover, OSA is regarded as the most
ommon secondary and treatable cause of systemic hy-
ertension (4). It is conceivable that OSA, acting in part
hrough increases in blood pressure (BP), may be the
rimary cause of HF in some individuals. The prevalence
nd coexistence of both conditions will increase as the
besity epidemic continues, and it is important to clarify
ow OSA might contribute to the promotion or progres-
ion of HF and its associated morbidity, which remains
nacceptably high.
See page 2008
Sympathetic activation is characteristic of HF and is
ssociated with disease progression and adverse prognosis
5). Therapies that attenuate sympathetic activity im-
rove HF outcomes (5). Obstructive sleep apnea, inde-
endent of obesity and comorbid states, is characterized
y sympathetic activation, tachycardia, impaired cardio-
ascular variability, endothelial dysfunction, and systemic
nflammation (6). These homeostatic disruptions are
resent even in OSA patients who are awake, normoxic,
nd free of detectable cardiovascular disease. They are
specially evident in patients with HF, for whom the
isruptions may have prognostic significance. Neural and
ascular dysregulation in awake, apparently healthy OSA
atients led us to propose the concept that repetitive
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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ultant: Respironics.octurnal hypoxemia occurring during OSA may activate
ompensatory and/or cardiovascular disease mechanisms
hat carry over into the daytime (7), and that this daytime
arryover effect may be attenuated by nocturnal continu-
us positive airway pressure (CPAP) (8).
In this issue of the Journal, Usui et al. (9) explore
hether this concept holds true for sympathetic activa-
ion in patients with HF. They present data for eight
atients with moderate to severe OSA and stable HF who
ere randomized to CPAP, compared to nine OSA and
F patients who received no OSA therapy. At one
onth, the investigators found that muscle sympathetic
erve activity (MSNA), BP, and heart rate—all measured
or 15 min upon awakening—were decreased in patients
ho received CPAP. Although the decline in sympa-
hetic burst frequency was modest, it nevertheless oc-
urred with decreases in BP, which itself would be
xpected to raise sympathetic drive. Furthermore, the
ecreases in heart rate suggest that the fall in sympathetic
ctivity with CPAP affects not only peripheral vascular
ympathetic activity but also cardiac sympathetic drive.
The demonstration that CPAP significantly decreased
ympathetic neural activation in patients with congestive
eart failure (CHF) and OSA while awake implies that
ntreated OSA in such individuals may be as harmful as
uboptimal treatment with beta-blockers. It is also pos-
ible that the decreases in sympathetic activation may be
ven greater during sleep, because nocturnal apneas and
ypoxia greatly augment sympathetic activity (7) and a
esponse to CPAP would be most marked during the
ight. It might also be expected that CPAP would not
nly attenuate sympathetic activation, but also lead to
mproved cardiac function. Small randomized, controlled
rials (10,11) have demonstrated that patients with CHF
nd OSA who were provided CPAP for one to three
onths experienced increases of left ventricular ejection
raction similar to or higher than might be expected with
harmacologic intervention over the same time periods.
These data have clear relevance to the care of HF
atients—a population with limited functional reserve and
n whom interventions (both favorable and adverse) can
uickly and significantly impact morbidity and mortality.
owever, although a non-pharmacologic approach, such as
PAP, for reducing BP, heart rate, and sympathetic activ-
ty, would also be an exciting potential strategy for reducing
HF morbidity and mortality, several considerations should
emper our enthusiasm until more data are available.
First, in this relatively small group of subjects (only eight
atients received intervention), the drop in sympathetic
ctivity was measured only for 15 min in the morning after
aking. Whether attenuation of sympathetic activity in HF
atients persists for the remainder of the day remains to be
stablished. This distinction is important, because sympa-
hetic activity likely exerts its pathophysiologic effects on
F throughout the day.
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June 21, 2005:2012–4 Editorial CommentSecond, whereas a randomized design is reported as a
alient aspect of this study, the researchers present data only
or patients with adequate MSNA recordings at both time
oints. Not reported are how many patients initially under-
ent randomization and whether assessments of MSNA
ecording quality (and thus patient inclusion or exclusion
rom the statistical analysis) were made systematically and in
blinded fashion. This approach detracts from the random-
zed design of the study and also, with the small number of
elected patients, from the reliability of the results.
Third, criteria for subject selection deserve comment.
lthough Usui et al. (9) report that subjects had been on
ptimal pharmacotherapy at highest tolerated dose for three
onths before enrollment, the subjects actually had subop-
imally controlled BP. The subjects in the control group
ere hypertensive (mean systolic BP 141 mm Hg), and
hose in the CPAP group had a mean systolic BP (135 mm
g) that is not typical of well-treated HF patients. As a
omparison, the mean systolic BP of participants in the
arvedilol Or Metoprolol European Trial (COMET) prior
o receiving beta-blocker therapy was 126 mm Hg and
ecreased further with therapy (12). Also, the resting heart
ates in both groups were higher than that which is
ncouraged and often achievable with optimal beta-
lockade in HF patients. In patients with OSA without HF,
reatment with CPAP consistently has been demonstrated
o lower daytime BP, primarily in hypertensive patients but
ot normotensive individuals (13). Thus, the CPAP treat-
ent effect in the study by Usui et al. (9) may very well be
ue to comorbid hypertension in their HF study sample. It
ould be necessary to study patients who are truly receiving
ptimal pharmacotherapy, with normal BP levels and con-
rolled heart rates, to identify the adjuvant therapeutic
ffects of CPAP on HF per se.
Fourth, no specific data are provided regarding beta-
locker use for the two treatment groups. Knowing about
oncomitant therapies is relevant because, as noted in work
y the same laboratory (14), beta blockers in CHF would be
xpected to directly affect the primary outcome of the study
i.e., sympathetic burst activity) as would digitalis. It also
ould be useful to know whether patients who were treated
ith CPAP were more likely to be on different doses or
ypes of beta blockers, because the pharmacologic properties
f various beta blockers differentially affect muscle sympa-
hetic nerve activity (15).
Finally, whether surrogate end points, such as changes in
eripheral sympathetic nerve traffic, translate into improve-
ents in important cardiovascular outcomes remains un-
nown. Also not known is whether OSA adversely affects
ortality of HF patients (16). While treatment with CPAP
n HF patients is often systematically beneficial and well
ecieved by patients, some data suggest that it is not always
ecessarily benign (17,18). These issues speak to the need
or carefully designed, adequately powered, randomized
rials of sufficient duration to clarify the effects of CPAPherapy on important outcomes in patients with OSA and
F.
Nevertheless, although preliminary, the findings of Usui
t al. (9) are of interest and raise a number of important
uestions. They add to our growing understanding of the
echanisms by which OSA may contribute to (and its
herapy may prevent) HF progression and adverse out-
omes. Their work provides impetus for development of
arger, more definitive studies that address the efficacy and
enefit of CPAP in the management of HF with coexistent
SA.
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